GASTROINTESTINAL STROMAL TUMOR (GIST)

This study tests a new drug, IDRX-42, for people with advanced gastrointestinal stromal tumors (GIST) that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and can shrink or control these tumors. About 278 adults who have already tried the stand…

This early-phase study tests an oral drug called HQP1351 in about 100 people with advanced gastrointestinal stromal tumors (GIST) or other solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and check for side effects, while al…

This early-stage trial tests a new oral drug called ziftomenib combined with imatinib in adults with advanced gastrointestinal stromal tumors (GIST) that have stopped responding to imatinib alone. The study will enroll about 157 people to see if the combination is safe and can sh…

This study tests a new drug called DCC-3009, alone or with other cancer treatments, in people with advanced GIST that has stopped responding to standard therapy. The goal is to see if the drug is safe and can shrink tumors. About 120 participants will receive the drug in 28-day c…

This study collects tissue and blood samples from people with stomach or esophageal cancer, as well as those at high inherited risk, to learn how genes and proteins contribute to these cancers. The goal is to better understand the disease, not to test a new treatment. About 100 p…

This study follows 400 people with gastrointestinal stromal tumors (GISTs) to collect tumor tissue and blood samples for research. Participants are monitored every 6-12 months for up to 10 years before surgery, and then for 5 years after. The goal is to better understand the dise…